Clinical trial · people

Follistatin-344 gene therapy: walk gains in some Becker patients

Checked against the paper Clinical trialPublished by PepVault

The takeaway

This small early human trial of follistatin delivered as gene therapy found walking gains in some people with Becker muscular dystrophy and no adverse effects, but it says nothing directly about injected follistatin peptides.

Kind
Clinical trial
Studied in
People
Number studied
6
Published
2015
Journal
Mol Ther

What they tested

The team tested whether delivering the follistatin gene (the FS344 form) into thigh muscles could improve walking in people with Becker muscular dystrophy, a muscle-wasting disease caused by missing or faulty dystrophin.

How the study was done

An early-stage (phase 1/2a) trial with no comparison group in 6 patients with Becker muscular dystrophy. Each got injections of a virus vector (AAV, adeno-associated virus) carrying FS344 into the quadriceps of both legs, at 3 × 10^11 vg/kg/leg in cohort 1 or 6 × 10^11 vg/kg/leg in cohort 2.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

PepVault for iPhone

Taking Follistatin-344? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

The main measure was the distance walked in a 6-minute walk test. In the lower-dose cohort, one patient walked 58 m farther, one 125 m farther, and one showed no change. In the higher-dose cohort, two patients improved by 108 m and 29 m, and one did not improve. No adverse effects were seen, and muscle samples showed less endomysial fibrosis (scarring between muscle fibers), fewer fibers with central nuclei, more normal fiber sizes and muscle hypertrophy (growth), most of all at the high dose.

What it doesn’t show

With only 6 patients and no placebo or untreated comparison group, the walking gains can't be firmly credited to the treatment, and results varied widely from person to person. It tested a one-time gene therapy injected into muscle, not a follistatin peptide given as a drug.

The paper

Mendell et al. A phase 1/2a follistatin gene therapy trial for becker muscular dystrophy. Mol Ther. 2015.

The compound

More studies on Follistatin-344

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking Follistatin-344? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo